Agios Pharmaceuticals (AGIO)
(Real Time Quote from BATS)
$40.36 USD
-0.56 (-1.37%)
Updated Oct 14, 2025 03:55 PM ET
After-Market: $40.22 -0.14 (-0.35%) 4:12 PM ET
5-Strong Sell of 5 5
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AGIO 40.36 -0.56(-1.37%)
Will AGIO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
Other News for AGIO
AGIO's price rises by 0.76% on October 13, though its technical setup remains stable.
AGIO forms Slingshot Bullish on October 10
AGIO forms Upper Bollinger Band Walk on October 9
COMMODORE CAPITAL LP Acquires Significant Stake in SAB Biotherapeutics Inc
AGIO rises 4.23% on October 8, leaving the technical picture intact